← Back to all trials
Completed
NCT06238778
Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec
Conditions: Diabetes Mellitus, Type 1
Sex: All
Ages: 18 Years – 79 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 227
Sponsor: Diasome Pharmaceuticals
Location: Marvel Clinical Research Huntington Beach California
Summary
The goal of this study is to see if directing insulin to the liver will improve the low blood sugar that sometimes happens when injecting insulin in Type 1 diabetes patients. Participants will use continuous glucose monitoring to measure the sugar levels in their blood, and work with the doctor to find the best doses. One group of patients will get the liver targeting insulin, and the other group will use insulin they normally use for treating Type 1 diabetes. The participant will be part of the study for up to 32 weeks.
Eligibility Criteria
Inclusion Criteria:
* clinical diagnosis Type 1 diabetes with C-peptide \= 6.5% and \
Source: ClinicalTrials.gov (NCT06238778). StuddyBuddy aggregates publicly available trial information.